Supercharge Your Innovation With Domain-Expert AI Agents!

Anti-trkb monoclonal antibodies and uses thereof

a monoclonal antibody and anti-trkb technology, applied in the field of anti-trkb monoclonal antibodies, can solve the problems of no successful examples of reagents that act as potent and selective in vivo agonists of trkb, and the outcome of bdnf protein therapy in clinics has been negativ

Inactive Publication Date: 2011-06-23
WYETH LLC
View PDF25 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

To date, there exist no successful examples of reagents that act as potent and selective in vivo agonists of TrkB.
While BDNF, as a recombinant protein, has been shown to increase neuronal survival and neuroregeneration in a number of CNS degenerative models in vitro and in vivo, the outcomes of BDNF protein therapy in clinics have been negative, most likely because BDNF has a short in vivo half-life.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-trkb monoclonal antibodies and uses thereof
  • Anti-trkb monoclonal antibodies and uses thereof
  • Anti-trkb monoclonal antibodies and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0101]This example describes the preparation and in vitro characterization and testing of a plurality of TrkB antibodies.

Materials and Methods

Immunogens

[0102]Murine anti-TrkB antibodies were prepared using a mixture of two protein immunogens: a first recombinant protein that includes the extracellular domain (ECD) of human TrkB (rhTrkB-ECD) (R&D systems, Inc., Cat. No. 397-TR / CF) and a second recombinant protein that includes the extracellular domain of murine TrkB (rmTrkB-ECD) (R&D system, Inc., Cat. No. 1494-TB / CF).

[0103]The extracellular domain of human TrkB is comprised of amino acid residues C32-H430 of the full length protein (which is set forth as SEQ ID NO:1, GenBank Accession No. NP—006171). rhTrkB-ECD was expressed in murine myeloma cell line NSO. The calculated molecular mass of monomeric rhTrkB-ECD is 44 kDa; however, when glycosylated it migrates as a broad band of 80-100 kDa in SDS-PAGE under reducing conditions.

[0104]The extracellular domain of murine TrkB is comprise...

example 2

[0135]This example describes further in vitro characterization and testing of a plurality of TrkB antibodies. In particular, this example describes experiments that were performed to assess the TrkB vs. TrkA and TrkC specificity of some of the antibodies of Example 1.

Materials and Methods

FACS Analysis

[0136]HEK-293 cells expressing human TrkA were detached from the plates with PBS containing 5 mM EDTA and transferred in to 5 ml Falcon tubes (Becton Dickinson, Cat. No. 352063) with 2×105 cells per tube. Cells were washed once with PBS by centrifuging at 800 rpm at 4° C. for 3 min, and incubated for 30 min at 4° C. with 100 μl of hybridoma culture supernatant or immune serum diluted in PBS with 1% FBS. The cells were washed 3 times with 1 ml PBS containing 1% FBS and incubated for 30 min at 4° C. in the dark with PE labeled goat anti-murine IgG, F(ab′)2 fragment (DAKO Corporation, Cat. No. R0480) in PBS containing 1% FBS. Cells were washed three times again and re-suspended in 250 μl P...

example 3

[0140]This example describes the in vivo testing of a plurality of TrkB antibodies in a rodent model of neonatal hypoxia-ischemia (HI).

Materials and Methods

Animals and Surgical Procedures

[0141]The rodent model of neonatal hypoxia-ischemia (HI) was based on the Levine procedure that is set forth in FIG. 11 (e.g., see Levine, Am. J. Pathol. 36:1-17, 1960; Rice et al., Ann. Neurol., 9:131-141, 1981 and Gidday et al., Neurosci. Lett. 168:221-224, 1994 each of which is incorporated herein by reference). Briefly, pups at P7 were anesthetized with 2.5% halothane and the left common carotid artery was permanently ligated. After the incisions were sutured, pups were returned to the home cage for recovery and feeding. Two hours later, pups were placed in individual containers, through which humidified 8% oxygen was flowed. After 2.5 hrs of a hypoxic ischemic period, the pups were returned to their home cages. For treatment, animals received a 5 μl intracerebroventricular injection of 0.1 or 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.

Description

PRIORITY INFORMATION[0001]The present application is a continuation of U.S. Ser. No. 11 / 446,875, which claims the benefit of U.S. Ser. No. 60 / 687,705, filed Jun. 6, 2005, the entire contents of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]Trk tyrosine kinase receptors are multi-domain single-transmembrane receptors that play an important role in a wide spectrum of neuronal responses including survival, differentiation, growth and regeneration. They are high affinity receptors for neurotrophins, a family of protein growth factors, which includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 / 5 (NT-4 / 5). The neurotrophins share highly conserved structural features, yet their unique amino acid sequences allow each member to elicit high affinity interactions with the extracellular domain of specific Trk receptors, namely TrkA, B or C. Thus, NGF is a preferred ligand for TrkA; BDNF and NT-4 / 5 ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/28C12N5/12A61P25/00A61P17/02A61P35/04A61P3/00A61P25/28G01N33/566C12N9/10
CPCA61K2039/505C07K16/2863C07K2316/95C07K2317/34C07K2317/622C07K2317/92C07K2319/30C07K2317/55C07K2317/75A61P17/00A61P17/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/18A61P25/24A61P25/28A61P3/00A61P31/00A61P35/00A61P35/04A61P37/00A61P43/00A61P3/10C07K16/28A61K39/395
Inventor CHO, SEONGEUNGILL, DAVINDER SINGHTAN, XIANG YANGQIAN, MING DIANA
Owner WYETH LLC
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More